Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)

NCT02242487 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT02242487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02242487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)
Lead sponsor
Acorda Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2015
Completion date
May 31, 2018
Enrollment
325 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease